Related Experiment Video
Updated: May 28, 2026
09:35
A High-content In Vitro Pancreatic Islet β-cell Replication Discovery Platform
Published on: July 16, 2016
β-Cell Generation: Can Rodent Studies Be Translated to Humans?
Françoise Carlotti1, Arnaud Zaldumbide, Johanne H Ellenbroek
1Department of Nephrology, Leiden University Medical Center, Postal Zone C3-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Journal of Transplantation
|October 19, 2011
Summary
New sources of beta cells are needed for type 1 diabetes treatment. This review explores postnatal cell types for beta cell replacement therapy, comparing rodent and human studies for clinical translation.
Area of Science:
- Endocrinology
- Regenerative Medicine
- Diabetes Research
Background:
- Allogeneic islet transplantation is a key strategy for type 1 diabetes.
- A significant shortage of donor organs limits current islet transplantation success.
- Alternative sources of functional beta cells are crucial for therapeutic advancement.
Purpose of the Study:
- To review potential postnatal cell sources for beta cell replacement therapy.
- To evaluate the clinical translatability of different cell sources for diabetes treatment.
- To highlight discrepancies between preclinical (rodent) and clinical (human) findings.
Main Methods:
- Literature review of studies on postnatal cell types for beta cell generation.
- Comparative analysis of in vivo and ex vivo studies in rodents.
- Examination of clinical data and studies on human cells.
Main Results:
- Various postnatal cell types show promise for beta cell generation.
- Significant differences exist between rodent model outcomes and human cell studies.
- Rodent data may not fully predict clinical efficacy for beta cell therapies.
Conclusions:
- Postnatal cells offer potential for beta cell therapy in type 1 diabetes.
- Addressing discrepancies between animal models and human studies is vital for clinical translation.
- Further research is needed to bridge the gap for effective beta cell replacement.
